Fintel reports that on February 17, 2026, Citigroup initiated coverage of Cullinan Therapeutics (NasdaqGS:CGEM) with a Buy recommendation. Analyst Price Forecast Suggests 184.02% Upside As of February ...
Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cullinan Therapeutics Inc (Symbol: CGEM), where a total of 5,055 contracts have traded so ...
CGEM has an interesting “modality‑agnostic” approach that focuses on targets first, then models yield the most promising candidates. This way, CGEM has built a relatively well-diversified oncology and ...
As of April 17, 2024, the average one-year price target for Cullinan Therapeutics is 26.86. The forecasts range from a low of 19.19 to a high of $37.80. The average price target represents a decrease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results